Saturated fat linked to higher mortality after prostate cancer

Clinical takeaway: Dietary fat advice for prostate cancer survivors is cardiovascular prevention, not cancer treatment. Swaps toward plant-based and monounsaturated fats tracked with 16-20% lower all-cause mortality. 

Men treated for nonmetastatic prostate cancer routinely ask what they can do beyond therapy to improve their odds, and their clinicians have had little evidence to support an answer. Most of these patients will live for years or decades after diagnosis, and over that horizon cardiovascular disease often claims more of them than the cancer does. With 3.5 million prostate cancer survivors in the US, the question of what to tell them belongs to primary care as much as to urology. 

What was known came mostly from the general population, where the composition of dietary fat shapes cardiovascular and overall mortality. Whether the same holds after a prostate cancer diagnosis has been harder to pin down: dietary trials in survivors have been small and short, built around biomarkers and metabolic measures rather than survival, and the few cohort analyses with mortality endpoints were limited by modest follow-up. A new prospective cohort analysis, the longest look yet at fat intake after diagnosis, now connects what these men eat to how they die. 

Men in the highest quintile of saturated fat intake after diagnosis had 24% higher all-cause mortality than those in the lowest, a difference that held after adjustment for clinical, lifestyle, and prediagnosis dietary factors. No fat measure moved prostate cancer-specific mortality in any model. The excess deaths traced instead to cardiovascular disease, where the highest saturated fat quintile carried a 42% higher mortality risk, with a wide confidence interval that still cleared significance. 

The substitution models put the finding in counseling terms. Replacing 10% of calories from animal fats with plant-based fats was associated with 16% lower all-cause mortality, and replacing 5% of calories from saturated fats with monounsaturated fats was tied to 20% lower. In absolute terms, estimated 10-year all-cause mortality ran 26.4% in the highest saturated fat quintile against 23.4% in the lowest, a gap of 3.0 percentage points. 

Animal fat on its own was associated with 14% higher all-cause mortality, but the confidence interval crossed null once prediagnosis intake entered the model, and the apparent links between saturated and animal fats and deaths from other cancers lost significance in the fully adjusted models. Trans, polyunsaturated, and plant-based fats individually showed no association with overall mortality. 

The analysis drew on 4,884 men with nonmetastatic prostate cancer in the Health Professionals Follow-Up Study, diagnosed between 1986 and January 2019 and followed a median of 12.8 years, with 3,040 deaths confirmed. Postdiagnosis fat intake came from validated food frequency questionnaires completed at least six months after diagnosis, and models adjusted for tumor characteristics, treatment, comorbidity, lifestyle, and prediagnosis intake. 

An invited commentary argues the substitution estimates are specific enough to build on: swapping animal for plant fats and saturated for monounsaturated fats could define the interventions for randomized trials in survivors at elevated cardiovascular or metabolic risk. In the meantime, the dietary pattern the data point toward already sits inside existing American Cancer Society survivorship guidance. 

"Clinicians should not present dietary fat modification as a proven prostate cancer–directed therapy, but neither should they ignore an important opportunity to promote health when patients are motivated to act," concludes the commentary. 

Source: Zhang Y, et al. (2026 Sep 2) JAMA Netw Open. Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer